Kornimate/medical-research-clean huggingface dataset:
progressive withdrawal esomeprazole and acid-related symptoms

Conditions: Stomach Diseases

Summary: rebound acid hypersecretion (rahs), defined as an increase in gastric acid secretion above pre-treatment levels after ppis therapy is observed within two weeks after withdrawal of treatment and could theoretically lead to acid-related symptoms such as heartburn, acid regurgitation, or dyspepsia that might result in resumption of therapy. a plausible physiologic theory for the rebound phenomenon suggests that long-term, elevated gastric ph caused by blockage of the proton-pumps stimulates compensatory gastrin release. interestingly, reimer et al. demonstrated the occurrence of rahs in healthy volunteers who had received eight weeks of esomperazole. the clinical symptoms occured in a different prevalence compared with placebo treated patients at ten weeks after withdrawal and until the end of the study (twelve weeks). twenty to twenty-two percent of patients displayed symptoms ten or twelve weeks after having discontinued ppis while they occured in 1.7-7% of placebo-treated patients. efforts should be pursued to restrict ppi therapy use to patients likely to benefit from it. in this context, we propose to investigate the benefit of a progressive decrease in doses of esomeprazole compared to a sudden discontinuation. this is a randomized, double-blind, placebo-controlled trial with 156 patients treated by esomeprazole 40mg since four weeks least, randomized to one week of placebo or one week of esomeprazole 20mg. we want to compare the prevalence of clinical gastrointestinal symptoms between patients with progressive discontinuation (one week of esomeprazole, 20mg, then discontinuation) or those with sudden discontinuation of esomeprazole 40mg.


Eligibility criteria:
inclusion criteria: * treatment by esomeprazole 40mg since 4 weeks or more * esomeprazole withdrawal decided by the clinician * male and female aged 18-90 years * volunteers to participate to the study * must understand and read french language * must be able to give a written informed consent exclusion criteria: * impairment of cognitive status * current indication to continue ppi treatment * history of erosive and ulcerative esophagitis, barrett esophagus, zollinger-ellison syndrome * short-term treatment of documented ulcer disease, as part of a combination regimen for helicobacter pylori (hp) eradication * prevention of ulcers due to non-steroidal anti-inflammatory drugs. * hepatic impairment (tp\<60%) * hypersensitivity to omeprazole (cyp2c19 activity) or esomeprazole * current pregnancy or current breastfeeding

Keywords: esomeprazole randomized study proton pump inhibitor gastric acid rebound randomized study esomeprazole
markers of inflammation in hematopoietic stem cell transplant

Conditions: Acute Graft Versus Host Disease

Summary: objectives: 1. to show feasibility and reproducibility of performing a multiplex ligation-dependent amplification procedure (rt-mlpa) 2. to describe the profile of changes in inflammatory gene products, using rt-mlpa, in pediatric patients receiving stem cell transplant 3. to determine if changes in a specific inflammatory product, or a combination of inflammatory products, can predict grade 2-4 acute graft-versus-host disease

allogeneic hematopoietic stem cell transplantation (hsct) is a successful treatment option for multiple malignant diseases (i.e. leukemia) and non-malignant disorders (i.e. metabolic disorders, genetic disorders, immunodeficiencies). unfortunately, transplantation from an hla-related family member is only available in 30-40% of stem cell transplant recipients. the other patients requiring hsct must then receive their stem cells from either a matched-unrelated donor (mud) or from cord blood. one major limitation upon receiving these unrelated stem cells are acute and chronic graft-versus-host disease. specifically looking at acute graft-versus-host disease (agvhd), up to 30% of the recipients of stem cells from an hla-identical related donor will develop greater or equal to grade 2 of agvhd despite immunosuppressive prophylaxis. the percentages of patients who develop agvhd from unrelated donors are even higher. the current standard treatment for agvhd is corticosteroids. unfortunately, only 40% of matched-siblings hsct cases and 25% of mud sct cases show a complete response to these steroids. those patients who do not respond to corticosteroids can show a dismal outcome. given the poor outcome with refractory gvhd, there has been a lot of interest in trying to predict who will get gvhd. these findings could lead to augmentation of gvhd prophylaxis. the purpose of this study is to look at a series of identified biomarkers to predict agvhd. once blood is drawn from the sct recipient, a multiplex ligation-dependent probe amplification (mlpa) will test different biomarkers in the blood to result in about 30-45 target sequences being examined simultaneously.

Eligibility criteria:
inclusion criteria: * objective #1: * healthy adult volunteers, affiliated to children's memorial hospital * male or female * objective #2 \& #3: * recipient undergoing an allogeneic stem cell transplant * receiving related or unrelated cord blood, related or unrelated bone marrow or peripheral blood stem cells * any pre-transplant regimen * ages of 0-21 years old * male or female exclusion criteria: * inability for subject/parent to understand study and therefore unable to consent * children under 7.0 kgs

Keywords: markers of inflammation acute graft versus host disease predicting agvhd
immidate effect of instrument assited soft tissue mobilization technique on chronic neck pain

Conditions: Neck Pain

Summary: chronic neck pain causes errors in joint position. there are studies in the literature suggesting that the application of instrument-assisted soft tissue mobilization improves the sense of joint position. there are no studies that acutely examine this practice on joint position sense and pain in the cervical region. as a result of our study, we will investigate the effects of instrument-assisted soft tissue mobilization in a single session on perception of pain and joint position.


Eligibility criteria:
inclusion criteria: * • being diagnosed with chronic neck pain, * to be in the age range of 18-65. exclusion criteria: * • those taking any analgesic medication * those with acute injury or infection, * those with open wounds, osteoporosis, * broken, * hematoma, those with acute cardiac, liver and kidney problems, * those with connective tissue disease, rheumatoid arthritis, osteoarthritis, cancer, * those with circulation problems, * those with peripheral vascular disease, epilepsy, surgery history in the cervical area

Keywords: joint position sense soft tissue mobilization neck pain
septal - success rate and clinical outcome of septal implant of ventricular defibrillation lead

Conditions: Ventricular Tachycardia; Ventricular Fibrillation

Summary: the purpose of this study is to determine the safety and efficacy of the implant of a icd lead of defibrillation in the septum of the right ventricle

the rate of success at implant and the positive clinical outcomes for the patients implanted with a lead of defibrillation at the septal site would make it possible to recommend this site as a "new standard" for implant of the defibrillation lead in the rv for icd.

Eligibility criteria:
inclusion criteria: * icd indication according to current guidelines exclusion criteria: * indication for cardiac resynchronisation therapy, absence of spontaneous ventricular rhythm, pacemaker dependency
expanded access program for rp in adults

Conditions: Retinitis Pigmentosa

Summary: this intermediate-size patient population expanded access program is to provide access to investigational product ocu400 for up to 75 patients with retinitis pigmentosa (rp) outside of the ongoing clinical trial phase 3 program for patients who do not have access to alternative food and drug administration (fda)-approved products for treatment of the disease.

this expanded access protocol provides access to ocu400 for a subset of patients. subjects will undergo specific ocular testing included in the study. subjects will follow-up with physical examination, review of concomitant medication, blood work and ocular examinations for up to 52 weeks (about 12 months) post dosing.

Eligibility criteria:
inclusion criteria: 1. males or females ≥18 years of age at the time of informed consent. 2. confirmed clinical and clia certified genetic diagnosis of rp (except subjects with ad-nr2e3 mutation) 3. presence of photoreceptors as determined by spectral-domain optical coherence tomography (sd-oct). exclusion criteria: 1. subject lacks evidence of outer nuclear layer, i.e., containing the nuclei of the retinal photoreceptors as determined by sd- oct. 2. considered unsuitable for any reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes by the investigator, or the sponsor after reviewing the subject medical history and condition. 3. previous treatment with a gene-therapy or cell therapy product, excluding ocu400. 4. previous treatment with any investigational drug or device within one year, excluding ocu400. 5. any contraindications for subretinal injection. 6. cataract surgery within 3 months. yag capsulotomy within 1 month. any other intraocular surgery within 6 months

Keywords: retinitis pigmentosa modifier gene therapy modified gene therapy rho rp nr2e3 subretinal injection
de-escalation radiotherapy in patients with low-risk hpv-related oropharyngeal squamous cell carcinoma

Conditions: Oropharyngeal Cancer

Summary: the purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.

the standard or usual treatment for this disease includes radiotherapy or radiotherapy combined with chemotherapy or antibody therapy. these treatments are highly effective at curing most patients with hpv-related cancer of the oropharynx, but short and long-term side effects from treatment can be significant.

Eligibility criteria:
inclusion criteria: * patients with pathologically proven diagnosis of hpv-related opscc * clinical stage t1-3 n0-1 m0 (uicc/ajcc 8th ed.) * patients must be eligible for definitive rt or crt * must be ≥ 18 years of age * must have an eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health economics questionnaires in either english or french * patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate * patients must be accessible for treatment and follow-up. investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. * in accordance with cctg policy, protocol treatment is to begin within 3 weeks of patient registration * women/men of childbearing potential must have agreed to use a highly effective contraceptive method * the following radiological investigations must be done within 8 weeks of randomization: ct or mr of head and neck (mri is recommended for base-of-tongue primary tumors); pet-ct scan. * patient must consent to provision of, and investigator(s) must confirm location and commit to obtain a representation of formalin-fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays described in section 12 (correlative studies) may be conducted. please see the correlative manual for details * patient must consent to provision of samples of blood and plasma (for circulating cell free dna) in order that the specific correlative marker assays described may be conducted. * patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. exclusion criteria: * previous chemotherapy or radiotherapy treatment for head and neck cancer * patients with an unknown primary.
a study of foy-305 in patients with sars-cov-2 infection (covid-19)

Conditions: SARS-CoV-2 Infection (COVID-19)

Summary: to assess the efficacy and safety of foy-305 in patients with sars-cov-2 infection (covid-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.


Eligibility criteria:
inclusion criteria: 1. inpatient or outpatient: inpatient 2. positive sars-cov-2 test by a method eligible for definitive diagnosis 3. enrollment in this study within 5 days after onset of symptoms of sars-cov-2 infection (covid-19) (for asymptomatic patients, enrollment in this study within 5 days after collection of the sample that tested positive) exclusion criteria: 1. receiving oxygen therapy 2. difficulty in swallowing oral medication 3. history of covid-19 4. history of vaccination against covid-19 5. taking camostat mesilate
a safety study of pregabalin in fibromyalgia

Conditions: Fibromyalgia

Summary: to evaluate the safety of pregabalin in patients with fibromyalgia.


Eligibility criteria:
inclusion criteria: * patients must meet the acr criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites. * patients must complete the double-blind study. exclusion criteria: * patients who experienced a serious adverse event during the previous fibromyalgia study, which was determined to be related to the study medication.
evaluating a tailored cognitive behavioral therapy for adolescent and young adult cancer patients

Conditions: Depression, Anxiety; Cancer

Summary: this project's overall goal is to test the feasibility, acceptability and efficacy of two coach-assisted, computer-based, cognitive- behavioral therapy (c-cbt) interventions in treating depression and anxiety in adolescent and young adult cancer survivors. the two coach-assisted interventions will be compared to the standard c-cbt intervention.

this will be a three-arm randomized controlled trial with two treatment arms and one control arm. participants in the first treatment arm will receive a coach-assisted c-cbt intervention called "beating the blues" (btb). a second treatment arm will receive a coach-assisted, animated c-cbt intervention called "entertain me well" (emw). both treatment arms will have 8 weekly sessions that contain core components of cbt. a coach will provide between-session support throughout the 8 sessions. the control arm will use the standard care of btb without coach assistance.

Eligibility criteria:
inclusion criteria: * cancer survivor, either receiving active treatment or completed cancer treatment * experiencing depression and anxiety as measured by phq-9 or gad-7 exclusion criteria: * severe medical or mental condition (e.g. suicidal ideation) * medical condition that prevents patients from operating a computer or tablet * receiving end-of-life care
acupressure for constipation in the elderly

Conditions: Constıpatıon

Summary: this study was carried out to determine the effect of acupressure applied to li4, cv12, st25 and st36 acupuncture points for a total of 21 minutes, three to each point, on the symptoms of constipation and quality of life of elderly individuals.

the study is a qualitative and quantitative mixed method, double-blind, randomized, placebo-controlled, pretest-posttest control group study. in this study; a total of 81 elderly individuals over the age of 65 and diagnosed with constipation in a family health center were included, 41 individuals in the acupressure group and 40 individuals in the placebo control group. ethics committee approval, informed voluntary consent of the elderly and all other necessary permissions to conduct the study were obtained before the study. the data of the study were collected using the individual identification form, the constipation assessment scale (cas), the constipation quality of life scale (pac-qol), the visual analog scale (vas), the individual follow-up form and the semi-structured interview form. acupressure was applied to individuals in the acupressure group every day for 12 days, and placebo acupressure was applied to individuals in the placebo acupressure group at the same time and in line with the same protocol. in addition, individual in-depth interviews were conducted with the individuals in the acupressure group after the applications were completed. quantitative data were evaluated using the ibm spss statistics for windows 24.0 package program. in the evaluation of quantitative data; independent groups t test / mann whitney u test, dependent groups t-test, two-way mixed pattern anova, multiple regression analysis (enter method) were used and p\<0.05 value was considered statistically significant. in the evaluation of qualitative data, descriptive and content analysis methods were used.

Eligibility criteria:
inclusion criteria: * aged 65 and over, * able to answer cognitive questions * able to do daily tasks unaided * experiencing two or more of the rome iv criteria exclusion criteria: * communication and adaptation difficulties, * malignant, intestinal obstruction, fecal incontinence, diarrhea, irritable bowel syndrome, abdominal infection, etc. have a contraindication to continue the intervention, addicted to bed * chronic pain requiring long-term analgesic intake and using psychiatric medication,

Keywords: acupressure constipation quality of life elderly people nursing
reset-sle: a phase 1/2 open-label study to evaluate the safety and efficacy of caba-201 in subjects with active systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus; Lupus Nephritis

Summary: reset-sle: a phase 1/2 open-label study to evaluate the safety and efficacy of caba-201 in subjects with active systemic lupus erythematosus

systemic lupus erythematosus (sle) is a chronic autoimmune disorder characterized by autoantibody production and abnormal b cell function. sle presents with fluctuating severity and may cause tissue damage in a variety of organs over time. lupus nephritis (ln) (renal involvement) is a common severe manifestation of sle, which can lead to significant morbidity and mortality. this study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, caba-201, that can be given to patients with either ln or sle without renal involvement, in two separate parallel cohorts, who have active disease. a single dose of caba-201 in patients who are pretreated with a standard regimen including cyclophosphamide (cy) and fludarabine (flu) will be evaluated.

Eligibility criteria:
inclusion criteria: * age ≥18 and ≤65 * a clinical diagnosis of sle, based on the 2019 european league against rheumatism (eular)/american college of rheumatology (acr) classification criteria for adult sle. * positive antinuclear antibody (ana) titer or anti-dsdna antibody at screening. * for ln subjects only, active, biopsy-proven ln class iii or iv, with or without the presence of class v, according to 2018 revised international society of nephrology/renal pathology society (isn/rps) criteria * for non-renal sle subjects only: active, moderate to severe sle exclusion criteria: * contraindication to leukapheresis * history of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites * active infection requiring medical intervention at screening * current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. * concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures * for ln subjects only: the presence of kidney disease other than active lupus nephritis * previous car t cell therapy * prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.

Keywords: caba-201 autoimmune disease anti-cd19 car-t therapy cellular therapy systemic lupus erythematosus lupus nephritis
effects of reflexology and generalized stretching in postmenopausal females.

Conditions: Postmenopausal Disorder

Summary: to determine the combined effects of reflexology and generalized stretching on insomnia, vasomotor symptoms and quality of life in postmenopausal females


Eligibility criteria:
inclusion criteria: * bmi less than 30 kg/m2 * residents of rural areas * stable vital signs * participants with natural cessation of menstrual periods for at least 12 months * moderate and severe hot flash exclusion criteria: * participants with history of hysterectomy surgical menopause females * participants with orthopedic disorder * participants taking sleeping pills * women suffer from pathological conditions for example cardiac disease, cancer impaired skin integrity * participants with history of recent bone fracture * severe pathology(eczema) of feet

Keywords: female insomnia postmenopausal quality of life reflexology
clinical trial on the efficacy and safety of chining decoction in the treatment of radiation stomatitis

Conditions: Head and Neck Cancer

Summary: this study evaluates the efficiency and safety of chining decoction to head and neck cancer patients with radioactive stomatitis. half of participants will receive chining decoction, while others will receive recombinant human epidermal growth factor (rhegf) spray.

this study uses randomized, controlled clinical research methods, through the observation of the treatment group (chining decoction orally) and control group (recombinant human epidermal growth factor rhegf spray on oral mucosal surface ) at different time points before and after radiotherapy, to evaluate the radiotherapy of acute radiation oral mucosa reaction (rtog grade), quality of life score (eortcqlq-h\&n35 scale), oral pain (vas score) and patient body weight changes of the two groups. at the same time，this study takes cast-off cells of oral mucosal to observe the microscopic characteristics of oral mucosa, and uses the elisa method to detect il-6 and tnf- alpha content in the saliva before and after radiotherapy.

Eligibility criteria:
inclusion criteria: * head and neck cancer patients with pathology and / or cytologic diagnosis; * age 18\~75 years old; * the expected life is more than 3 months; * the karnofsky score (karnofsky) ≥70 points; * the first course of radiotherapy in patients; * patients had not received any anti tumour therapies for example of operation, radiotherapy,chemotherapy, biological treatment or isotope therapy system; * patients volunteered to participate in this test and signed the informed consent, understand the purpose and test steps of the test, good compliance, comply with the relevant requirements of this test scheme; * no history of oral ulcer and salivary gland diseases exclusion criteria: * that do not meet the above the inclusion criteria; * advanced critical cases, the expected survival is less than 3 months; * the patients had serious complications, such as cachexia, hepatic encephalopathy, gastrointestinal bleeding and coagulation functionobstruction, su ch as abnormal; * the submandibular gland pathological changes; * during radiotherapy taking other drugs in patients with treatment of stomatitis; * the patients with serious heart, brain, liver, kidney function

Keywords: head and neck cancer chemoradiotherapy radioactive stomatitis